News
XLO
9.01
-0.44%
-0.04
Xilio Advances XTX501; FDA Clears IND For Phase 1/2 Trial
NASDAQ · 1d ago
Xilio Therapeutics GAAP EPS of -$0.33, revenue of $18.7M
Seeking Alpha · 2d ago
*Xilio Therapeutics 2Q Loss/Shr 33c >XLO
Dow Jones · 2d ago
Press Release: Xilio Therapeutics Reports Second -2-
Dow Jones · 2d ago
Weekly Report: what happened at XLO last week (0803-0807)?
Weekly Report · 4d ago
Weekly Report: what happened at XLO last week (0727-0731)?
Weekly Report · 08/03 09:04
Weekly Report: what happened at XLO last week (0720-0724)?
Weekly Report · 07/27 09:04
Weekly Report: what happened at XLO last week (0713-0717)?
Weekly Report · 07/20 09:04
Weekly Report: what happened at XLO last week (0706-0710)?
Weekly Report · 07/13 09:04
Weekly Report: what happened at XLO last week (0629-0703)?
Weekly Report · 07/06 09:04
Press Release: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Dow Jones · 06/29 11:30
Weekly Report: what happened at XLO last week (0622-0626)?
Weekly Report · 06/29 09:04
Weekly Report: what happened at XLO last week (0615-0619)?
Weekly Report · 06/22 09:04
Weekly Report: what happened at XLO last week (0608-0612)?
Weekly Report · 06/15 09:04
Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes
TipRanks · 06/12 21:29
Weekly Report: what happened at XLO last week (0601-0605)?
Weekly Report · 06/08 09:04
Weekly Report: what happened at XLO last week (0525-0529)?
Weekly Report · 06/01 09:04
Weekly Report: what happened at XLO last week (0518-0522)?
Weekly Report · 05/25 09:05
Cancer Stocks That Are Advancing the Future of Oncology Care
NASDAQ · 05/18 16:00
Weekly Report: what happened at XLO last week (0511-0515)?
Weekly Report · 05/18 09:05
More
Webull provides a variety of real-time XLO stock news. You can receive the latest news about Xilio Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About XLO
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Its pipeline products include Vilastobart, Efarindodekin alfa, XTX501, and masked T cell engagers. Vilastobart is an investigational masked, Fc-enhanced anti-CTLA-4 designed to block CTLA-4 and deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). XTX501 is a novel bispecific PD-1 / masked IL-2 designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function. Its masked T cell engager programs consist of PSMA and STEAP1 with co-stimulation and CLDN18.2. The masked T cell engagers include molecules with one or more tumor-associated antigen (TAA) binding domains and a CD3 targeting domain.